Dyadic International Inc (DYAI)

Currency in USD
0.987
-0.012(-1.20%)
Closed·
0.9870.000(0.00%)
·
DYAI is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
0.9701.020
52 wk Range
0.7112.143
Key Statistics
Prev. Close
1
Open
0.99
Day's Range
0.97-1.02
52 wk Range
0.711-2.143
Volume
47.22K
Average Volume (3m)
240.84K
1-Year Change
-44.86%
Book Value / Share
0.07
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
DYAI Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
7.000
Upside
+609.22%
Members' Sentiments
Bearish
Bullish
ProTips
Significant return over the last week

Dyadic International Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Buy
Moving Averages
Strong Buy

Dyadic Company Profile

Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells industrial enzymes and other proteins in the United States and internationally. It utilizes the C1 platform in pharmaceutical applications, including the development and production of pharmaceutical products. The company offers Dapibus, a protein production platform that enable the rapid development and large-scale manufacture of cost-effective enzymes, proteins, metabolites, and other biologic products for life sciences, food and nutrition, and bioindustrial applications. In addition, it develops DYAI-100, a C1-SARS-CoV-2 recombinant protein RBD vaccine candidate and first C1, which is in phase 1 clinical trial to produce protein tested in humans. The company has a research and development agreement with VTT Technical Research Centre of Finland, Ltd.; license agreement with South Africa’s Rubic One Health; joint development agreement with a Global Food Ingredient Company; and sub-license agreement with Abic Biological Laboratories Ltd., Alphazyme, LLC, and Abic Biological Laboratories Ltd. Dyadic International, Inc. was founded in 1979 and is headquartered in Jupiter, Florida.

Dyadic International Inc Earnings Call Summary for Q3/2025

  • Dyadic International (DYAI) reported Q3 2025 EPS of -$0.06, missing forecasts by 20%, with revenue of $1.165 million falling 22.67% below expectations, causing shares to drop 7.42% in after-hours trading.
  • Revenue declined from $1.968 million year-over-year, primarily due to reduced license and milestone revenue, though grant revenue increased by $815,000. Cash position stands at $10.4 million as of September 30.
  • The company completed its first commercial bulk protein product sale and rebranded as Dyadic Applied Biosolutions, signaling its transition 'from potential to execution' as a commercial organization.
  • Management expects growth in product revenue within life sciences and food/nutrition markets, targeting bulk sales to distributors and manufacturers while expanding its product portfolio in cell culture media.
  • CEO Mark Emalfarb highlighted efforts to 'mimic human breast milk' through product development, while the company raised $4.9 million through a public offering of 6,052,000 shares at $0.95 per share.
Last Updated: 08/12/2025, 13:12
Read Full Transcript

Compare DYAI to Peers and Sector

Metrics to compare
DYAI
Peers
Sector
Relationship
P/E Ratio
−4.9x−2.3x−0.6x
PEG Ratio
1.65−0.150.00
Price/Book
13.7x2.4x2.6x
Price / LTM Sales
10.7x90.9x3.2x
Upside (Analyst Target)
-23.1%41.8%
Fair Value Upside
Unlock−5.9%5.1%Unlock

Analyst Ratings

1 Buy
0 Hold
0 Sell
Ratings:
1 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 7.000
(+609.22% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
H.C. Wainwright
Buy3.00+203.95%-New Coverage23/10/2025
Craig-Hallum
Buy5.00+406.59%-New Coverage08/09/2025

Earnings

Latest Release
Nov 12, 2025
EPS / Forecast
-0.06 / -0.05
Revenue / Forecast
1.16M / 1.50M
EPS Revisions
Last 90 days

Dyadic (DYAI) Income Statement & Profits

People Also Watch

0.870
CETY
-2.14%
1.8600
VEEE
-7.46%
4.490
RLMD
0.00%

FAQ

What Is the Dyadic (DYAI) Share Price Today?

The live Dyadic share price today is 0.987

What Stock Exchange Does Dyadic (DYAI) Trade On?

Dyadic is listed and trades on the Nasdaq Stock Exchange.

What Is the Ticker (Stock Symbol) for Dyadic?

The stock symbol (also called a 'ticker') for Dyadic is "DYAI."

What Is the Current Dyadic Market Cap?

As of today, Dyadic market capitalisation is 35.73M.

What Is Dyadic's (DYAI) Earnings Per Share (TTM)?

The Dyadic EPS is currently -0.22 (Trailing Twelve Months).

When Is the Next Dyadic Earnings Date?

Dyadic's next earnings report will be released on 30 Mar 2026.

Is DYAI a Buy or Sell From a Technical Analyst Perspective?

Based on today's Dyadic moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Dyadic Stock Split?

Dyadic has split 0 times. (See the DYAI stock split history page for full effective split date and price information.)

How Many Employees Does Dyadic Have?

Dyadic has 6 employees.

What is the current trading status of Dyadic (DYAI)?

As of 24 Dec 2025, Dyadic (DYAI) is trading at a price of 0.987, with a previous close of 1.000. The stock has fluctuated within a day range of 0.970 to 1.020, while its 52-week range spans from 0.711 to 2.143.

What Is Dyadic (DYAI) Price Target According to Analysts?

The average 12-month price target for Dyadic is USD7, with a high estimate of USD9 and a low estimate of USD5. 1 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +609.22% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.